UNSPSC 51142308: Nalorphine

This classification denotes a narcotic antagonist with the molecular formula C19H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U59WB2WRY2, chemically known as 7,8-didehydro-4,5-epoxy-17-(2-propenyl)morphinan-3,6-diol but generally known as nalorphine, which bears US NIH Compound Identifier 5284595. European Medicines Agency schedules Nalorphine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09141MIG.

UNSPSC 51142308 Nalorphine is a Commodity code covering opioid antagonist pharmaceuticals and related drug-deactivation products procured by state and local health agencies and cooperative purchasing organizations. Recent solicitations show state and local governments buying naloxone (the primary active opioid antagonist) and safe drug deactivation systems to support community health and emergency response programs, as well as broader generic pharmaceutical supply agreements that may include nalorphine-class products as line items within larger multi-drug contracts. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions. The mix reflects both direct procurement by individual counties and regional health systems and indirect purchasing through cooperative agreements that serve multiple state agencies and local entities.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would include pharmaceutical products sourced outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and over-the-counter products with a March 26, 2026 response deadline, specifying distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co. Vendors must demonstrate cGMP and Drug Supply Chain Security Act compliance, maintain relationships with authorized wholesalers, and accept pricing models including flat price, net price formats, and WAC-minus structures. All three solicitations require electronic submission and include standard compliance certifications such as E-Verify and drug-free workplace verification.